Half-Year 2022 Financial and Clinical Trials Update
Roche Group development pipeline
Phase I (49 NMES + 11 Als)
RG6007
RG6026
RG6058
HLA-A2-WT1 x CD3
glofitamab monotherapy + combos
tiragolumab combos
AML
RG7828
heme tumors
heme & solid tumors
RG6129
RG6160
RG6171
RG6076 CD19-4-1BBL combos
HLA-A2-MAGE-A4 x CD3
cevostamab (FcRH5 x CD3)
giredestrant (SERD)
heme tumors
CHU
CHU
Lunsumio (mosunetuzumab)
monotheraphy + combos
FIXa x FX
RG6026
glofitamab +chemo
heme tumors
glypican-3 x CD3
solid tumors
CHU
codrituzumab
hemophilia
solid tumors
HCC
RG6058
tiragolumab + T
tiragolumab +T+chemo
tiragolumab +T+chemo
tiragolumab +T
r/r multiple myeloma
CHU
CD137 switch antibody
solid tumors
tiragolumab + T
solid tumors
CHU
LUNA18
solid tumors
RG6114
RG6156
inavolisib (mPI3K alpha inh)
EGFRvIII x CD3
CHU
SPYK04
solid tumors
solid tumors
SQZ
PBMC vaccine
glioblastoma
solid tumors
RG6287
IBD
RG6180
autogene cevumeran + T
solid tumors
RG6341
asthma
RG6185
belvarafenib (pan-RAF inh) + Cotellic + T
solid tumors
RG6107
RG6139
RG6180
RG6354
RG6357
crovalimab
PD1 x LAG3
SPK-8011
RG6418
RG6189
FAP-CD40 ±T
solid tumors
selnoflast (NLRP3 inh)
inflammation
RG6194
runimotamab (HER2 x CD3)
BC
RG6315
RG7828
immunologic disorders
Lunsumio (mosunetuzumab)
RG6234
GPRC5D x CD3
multiple myeloma
RG7880
efmarodocokin alfa
SLE
aGVHD
RG6264
Phesgo OBI
HER2+ BC
RG6358
RG7601
CHU
RG6149
SPK-8016
Venclexta + carfilzomib
Oncolytic Type 5 adenovirus
RG6006
Abx MCP
astegolimab (Anti-ST2)
bacterial infections
RG6279
PD1-IL2v + T
solid tumors
RG6319
LepB inhibitor
RG6299+
ASO factor B
complicated urinary tract infection
autogene cevumeran + pembrolizumab
zinpentraxin alfa (PRM-151)
hemophilia A with inhibitors to factor VIII
r/r MM t(11;14)
esophageal cancer
COPD
IgA nephropathy
Phase II (22 NMES + 11 Als)
Roche
1L ctDNA high risk DLBCL
NSCLC
1L non-squamous NSCLC
NSCLC neoadj-adj
cervical cancer
1L PD-L1+mSCCHN
sickle cell disease
solid tumors
1L melanoma
myelofibrosis
hemophilia A
RG6286
colorectal cancer
RG7854/RG79
RG6035
BS-CD20 MAb
RG6290
MAGE-A4 ImmTAC + T
solid tumors
RG6091
RG6292
CD25 MAb ±T
solid tumors
rugonersen (UBE3A LNA)
multiple sclerosis
Angelman syndrome
TLR7 ago(3)/CPAM (2)/
07/RG6346/
HBV
RG60841
siRNA/PDL1 LNA
RG6163
psychiatric disorders
RG6359
SPK-3006
Pompe disease
RG6323
IL15/IL15Ra-Fc + T
solid tumors
RG6182
RG6330
KRAS G12C
solid tumors
RG6237
latent myostatin
RG6333
CD19 x CD28+ glofitamab
r/r NHL
RG6289
RG6344
BRAF inhibitor (3)
solid tumors
RG7637
RG6392
RG6433
SHP2i
RG6440
TGFB (SOF 10)
RG6526**
camonsertib
RG7446
Morpheus platform
oncology
solid tumors
solid tumors
solid tumors
solid tumors
RG6120
VEGF-Ang2 DutaFab
RG7601
Venclexta + azacitidine
r/r MDS
RG6312
RG6351
RG6501*
RG7921
CHU
NME
OpRegen
neurodegenerative diseases
neuromuscular disorders
Alzheimer's
neurodevelopmental disorders
nAMD
geographic atrophy
retinal disease
geographic atrophy
nAMD
RG6100
semorinemab
Alzheimer's
RG6102
BS-gantenerumab
Alzheimer's
RG6237
latent myostatin + Evrysdi
SMA
RG6416
bepranemab
Alzheimer's
RG7412
crenezumab
familial Alzheimer's healthy pts
RG7816
alogabat (GABA Aa5 PAM)
ASD
RG7906
ralmitaront
RG7935
prasinezumab
AMY109
endometriosis
RG7802
cibisatamab + T
solid tumors
RG6147
RG6179
RG7774
galegenimab (HtrA1)
RG7827
FAP-4-1BBL monotherapy + combos
solid tumors
RG6299+
ASO factor B
schizophrenia
Parkinson's
geographic atrophy
DME
retinal disease
geographic atrophy
1combination platform
Status as of July 21, 2022
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other
CHU Chugai managed
+IONIS managed
SQZ-SQZ Biotechnology managed
*Lineage Cell Therapeutics managed
**Repare Therapeutics managed
RG-No-Roche/Genentech
T=Tecentriq
BS Brain Shuttle
OBI-On-Body Delivery System
74View entire presentation